Display options
Share it on

Case Rep Pathol. 2017;2017:8257590. doi: 10.1155/2017/8257590. Epub 2017 May 11.

Keratoacanthoma of the Nasal Septum Secondary to Ranibizumab Use.

Case reports in pathology

Jason E Cohn, Hilary M Caruso Sales, Giang Huong Nguyen, Harvey Spector, Kenneth Briskin

Affiliations

  1. Department of Otolaryngology-Head and Neck Surgery, Philadelphia College of Osteopathic Medicine, 4190 City Line Avenue, Philadelphia, PA, USA.
  2. Department of Dermatology, University of Colorado Anschutz Medical College, 1665 Aurora Court, Aurora, CO, USA.
  3. Department of Pathology, Crozer-Chester Medical Center, One Medical Center Boulevard, Upland, PA, USA.
  4. Department of Otolaryngology-Head and Neck Surgery, Crozer-Chester Medical Center, One Medical Center Boulevard, Upland, PA, USA.

PMID: 28584672 PMCID: PMC5443992 DOI: 10.1155/2017/8257590

Abstract

Keratoacanthoma (KA) is a benign epithelial tumor that typically presents as a firm, cone-shaped, flesh-colored nodule with a central horn-filled crater. KA is considered to be a low-grade variant of squamous cell carcinoma (SCC). We report a rare case of a 72-year-old male who presented with a KA involving the nasal septum, possibly related to ranibizumab use. A flesh-colored lesion on the right anterior nasal septum lesion was visualized on examination. Histologic examination revealed a well-circumscribed, dome-shaped central crater filled with keratin, well-differentiated squamous epithelium with ground-glass cytoplasm with pushing margins, and intraepithelial microabscesses establishing the diagnosis of KA. KA of the nasal septum has only been reported once in the literature. This case is unusual because it normally presents on sun-exposed areas. Additionally, this patient was taking ranibizumab, a vascular endothelial growth factor (VEGF) inhibitor for macular degeneration. Despite ranibizumab not being directly linked to precancerous and cancerous skin lesions, agents in this medication class have been. Although it is difficult to prove associations in this isolated case, the role of ranibizumab causing cutaneous lesions should be further investigated.

References

  1. Clin Ophthalmol. 2013;7:185-91 - PubMed
  2. Pak J Biol Sci. 2009 Oct 15;12(20):1385-7 - PubMed
  3. Am J Dermatopathol. 1997 Feb;19(1):10-5 - PubMed
  4. Acta Otorhinolaryngol Ital. 2013 Dec;33(6):428-30 - PubMed
  5. J Clin Oncol. 2009 Aug 10;27(23):e59-61 - PubMed
  6. Ann Otolaryngol Chir Cervicofac. 1979 Sep-Oct;96(10-11):767-79 - PubMed
  7. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2010 Mar;24(5):214-6 - PubMed
  8. Radiographics. 2008 Jan-Feb;28(1):205-24; quiz 326 - PubMed
  9. J Drugs Dermatol. 2004 Nov-Dec;3(6):680-2 - PubMed
  10. Head Face Med. 2010 Jun 04;6:7 - PubMed
  11. Am J Rhinol Allergy. 2016 May;30(3):83-90 - PubMed
  12. J Am Acad Dermatol. 2003 Feb;48(2 Suppl):S35-8 - PubMed
  13. Otolaryngol Head Neck Surg. 1990 Sep;103(3):472-5 - PubMed
  14. Clin Exp Dermatol. 2011 Jun;36(4):369-71 - PubMed
  15. Am J Dermatopathol. 2014 Mar;36(3):252-7 - PubMed
  16. Otolaryngol Head Neck Surg. 1985 Feb;93(1):112-6 - PubMed
  17. Br J Clin Pract. 1995 Jan-Feb;49(1):52 - PubMed
  18. J Am Acad Dermatol. 2009 Sep;61(3):522-7 - PubMed
  19. Actas Dermosifiliogr. 2014 Dec;105(10 ):900-12 - PubMed
  20. J Dtsch Dermatol Ges. 2010 Apr;8(4):243-9 - PubMed
  21. J Am Acad Dermatol. 1994 Jan;30(1):1-19; quiz 20-2 - PubMed
  22. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2013 Dec;27(23):1337-8 - PubMed
  23. JAAD Case Rep. 2015 Jul 29;1(5):274-6 - PubMed
  24. J Am Acad Dermatol. 2015 Feb;72(2):203-18; quiz 219-20 - PubMed

Publication Types